How the Skin Microbiome Changes with Age

The skin microbiome is the community of microorganisms—bacteria, fungi, and viruses—that colonise the skin surface. It is not a single entity but a dynamic ecosystem whose composition varies by body site, and which is shaped in part by skin barrier integrity and the local immune environment. The formal term used in the registered research literature is simply "skin microbiome"; no sequence, formula, or molecular weight applies, because the object of study is a microbial community rather than a single molecule. The work centres on the relationship between skin barrier function, cutaneous inflammation, and the microbial populations that colonise the skin, with the Th2 inflammatory pathway and antimicrobial peptide expression among the mechanisms examined.

Age-related change in this community is studied mainly through two windows: early life, when the skin is first colonised, and later life, when barrier decline and chronic low-grade inflammation are thought to alter the skin environment. The evidence below is drawn from registered clinical studies; where a finding comes from a specific population, that population is named.

Research Studies

Vernix caseosa retention and atopic dermatitis prevention in newborns

Vernix caseosa is a naturally occurring, white, creamy substance that covers the skin of newborns at birth and forms during the last trimester. A registered trial is examining whether retaining vernix caseosa in newborns can serve as primary prevention for atopic dermatitis (AD), also known as eczema [1]. The rationale rests on the observation that genetic and environmental factors contribute to AD, especially those related to skin-barrier integrity and the skin microbiome during early life [1]. This study addresses the earliest period of microbiome establishment, not ageing skin.

Skin barrier function and inflammation in older adults

The BIA Study is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin [3]. Its overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation [3]. Secondary objectives include determining the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers [3]. This is the most direct registered investigation of age-related skin microbiome change in the evidence set, and it is a feasibility pilot.

Topical ivermectin and the skin microbiome in rosacea

A single-site, 16-week open-label study at the University of California, San Diego, assessed topical ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome in rosacea [4]. Investigators first measured serine protease activity, cathelicidin, and the skin microbiome of all subjects; all subjects then received ivermectin topical cream daily for 12 weeks, with monthly visits scoring facial redness and papule counts [4]. This study concerns an inflammatory facial dermatosis, not ageing as such, but it is one of the few registered protocols that directly sequences the skin microbiome alongside an inflammatory marker.

Lymphedema and Th2-related inflammation

An observational, cross-sectional study aims to characterise the biological profile of primary and secondary lymphedema across five interconnected domains: T helper 2 (Th2)-related inflammation, endothelial activation, metabolic dysfunction, lymphatic biology, and tissue fibrosis [2]. Lymphedema is traditionally considered a disorder of impaired lymphatic drainage, but increasing evidence suggests its development and progression involve chronic inflammation, endothelial dysfunction, metabolic alterations, abnormal lymphatic signaling, adipose tissue accumulation, and progressive tissue fibrosis [2]. This study does not measure the skin microbiome; it is included because it maps the inflammatory and tissue-remodelling context in which skin microbial communities are studied.

Comparison of study populations and measured outcomes

What the evidence does not yet establish

None of the registered studies in this evidence set reports a completed, age-stratified map of the skin microbiome from infancy to old age. The BIA Study is a pilot whose primary objective is to determine the feasibility of a larger trial [3]. The vernix caseosa trial addresses primary prevention of atopic dermatitis in newborns [1]. The ivermectin study is open-label and single-site [4]. The lymphedema study is observational and cross-sectional [2]. Claims that a specific microbial shift causes a specific age-related skin outcome are not supported by these records.

Animal and in vitro evidence

The evidence block provided for this page contains no animal-only or in vitro studies. All four records are registered human clinical studies. Any statement about mechanism beyond what these protocols measure would be extrapolation and is therefore omitted.

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research use only. We do not provide dosing, treatment, or medical guidance, and nothing on this page should be taken as a recommendation for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis — ClinicalTrials.gov
• [2] Biological Profile of Primary and Secondary Lymphedema: Inflammatory, Endothelial, Metabolic, Lymphatic, and Fibrotic Markers — ClinicalTrials.gov
• [3] Skin Barrier Function and Inflammation in Aging: The BIA Study — ClinicalTrials.gov
• [4] Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation — ClinicalTrials.gov